• OrbiMed Advisors, a Scribe Therapeutics director, reported an increase in indirect common-stock holdings to 1,348,825 shares.
• The filing shows the acquisition of 1 million common shares at USD 15.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scribe Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000947871-26-000733), on July 29, 2026, and is solely responsible for the information contained therein.